In Highlights – First six months of Sales update Sales increased by 9% and by 5% at CER to DKK 59.3 billion • International Operations sales growth of 13% and of 12% • North America Operations sales growth of 5% and decline • Diabetes and Obesity combined sales growth of 10% and of 6% 56%, and 3% at CER, respectively • Sales of Ozempic® were 3,750 million Danish kroner and it ha R&D events • Initiation of semaglutide high dose trial (SUSTAIN FORTE), oral semaglutide CVOT (SOUL). The four trials will enrol appro • Oral semaglutide submitted in Japan for treatment of type 2 • Victoza® approved for use in children and adolescents with typ CHMP in the EU • Xultophy® approved in Japan and Ryzodeg® approved in Ch Financials & outlook Operating profit increased by 12% and by 6% at CER to DKK 2 Net profit decreased by 5% to DKK 20.0 billion and diluted ea 2019 financial outlook reflects robust sales growth outlook and • Sales growth now expected to be 4-6% at CER (reported: aro • Operating profit growth now expected to be 4-6% at CER (rep An interim dividend of DKK 3.00 for each Novo Nordisk A and B Note: Unless otherwise specified sales and growth numbers are as reported in Danish kroner CER: Constant exchange rates; CHMP: Committee for Medicinal Products for Human Use; CVOT: Cardiovascul
Download PDF file